Premium Nahrungsergänzungsmittel | artgerecht

CD86 (B7-2): Function, Significance & Therapy

CD86 is a costimulatory molecule expressed on immune cells that is essential for T lymphocyte activation and plays a central role in the adaptive immune response.

Regular tips about health Regular tips about health

Things worth knowing about "CD86"

CD86 is a costimulatory molecule expressed on immune cells that is essential for T lymphocyte activation and plays a central role in the adaptive immune response.

What is CD86?

CD86, also known as B7-2, is a type I transmembrane glycoprotein belonging to the B7 protein family. It is expressed on the surface of antigen-presenting cells (APCs), including dendritic cells, macrophages, B lymphocytes, and activated monocytes. CD86 is a key costimulatory ligand that acts at the interface between innate and adaptive immunity.

Function and Mechanism of Action

CD86 exerts its effects primarily through binding to two receptors on T lymphocytes:

CD28: Binding of CD86 to CD28 provides the costimulatory signal (Signal 2) required for full T cell activation. Without this signal, the T cell remains inactive despite antigen recognition, entering a state of anergy.
CTLA-4 (CD152): Binding to CTLA-4 delivers an inhibitory signal, downregulating T cell activation and playing a critical role in immune tolerance.

Expression of CD86 on APCs is induced by inflammatory signals, pathogen-associated molecular patterns (PAMPs), and cytokines. Compared to its close relative CD80 (B7-1), CD86 is expressed more rapidly and at higher levels on activated APCs, making it the primary costimulatory ligand during early immune responses.

Clinical Significance

Autoimmune Diseases

Dysregulated CD86 expression has been linked to various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis. Excessive costimulation can lead to uncontrolled activation of autoreactive T cells.

Transplant Medicine

In organ transplantation, CD86 plays a significant role in rejection responses. Blockade of the CD80/CD86-CD28 pathway by the fusion protein Belatacept (a CTLA-4-Ig construct) is used clinically to prevent kidney transplant rejection.

Oncology and Immunotherapy

In cancer therapy, CD86 is of growing interest. Tumors can exploit the CD86-CTLA-4 axis to evade immune surveillance. Checkpoint inhibitors such as Ipilimumab, which block CTLA-4, act on this pathway to enhance anti-tumor T cell activity. Additionally, CD86 is being investigated as a biomarker for immune activity in tumor microenvironments.

Allergies and Asthma

Research suggests that CD86 may be involved in skewing T cell responses toward a Th2 phenotype, which is characteristic of allergic diseases and asthma.

Diagnostic Relevance

CD86 expression is measured on immune cells using flow cytometry (FACS) and serves as an activation marker for antigen-presenting cells. In research and clinical diagnostics, CD86 is used to characterize immune cell populations and assess immune status, for example in the evaluation of immunodeficiencies or autoimmune conditions.

Therapeutic Approaches

Targeted modulation of the CD86 signaling pathway is an active area of research. Key therapeutic strategies include:

CTLA-4-Ig fusion proteins (e.g., Abatacept, Belatacept): Inhibit the CD86/CD80-CD28 interaction, dampening excessive immune responses in autoimmune diseases and post-transplantation.
Anti-CTLA-4 antibodies (e.g., Ipilimumab): Block the inhibitory signaling axis and amplify T cell-mediated immune responses against tumors.
CD86-directed approaches in preclinical research: Utilizing CD86 as a target structure for bispecific antibodies or CAR-T cell therapies.

References

Sharpe, A.H. & Freeman, G.J. (2002). The B7-CD28 superfamily. Nature Reviews Immunology, 2(2), 116–126.
Linsley, P.S. & Golstein, P. (2021). T-cell costimulatory pathways: B7/CD28 superfamily in immunity and tolerance. In: Fundamental Immunology (8th ed.), Paul, W.E. (ed.), Wolters Kluwer.
Vincenti, F. et al. (2010). Costimulation blockade with belatacept in renal transplantation. New England Journal of Medicine, 362(21), 1875–1885.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.